1. Home
  2. GAU vs IRWD Comparison

GAU vs IRWD Comparison

Compare GAU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$1.86

Market Cap

606.0M

Sector

N/A

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.76

Market Cap

658.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAU
IRWD
Founded
1999
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.0M
658.5M
IPO Year
2006
2009

Fundamental Metrics

Financial Performance
Metric
GAU
IRWD
Price
$1.86
$3.76
Analyst Decision
Buy
Buy
Analyst Count
2
3
Target Price
$4.08
$7.67
AVG Volume (30 Days)
2.9M
2.5M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.24
Revenue
N/A
$298,276,000.00
Revenue This Year
$82.77
$57.95
Revenue Next Year
$29.09
$4.39
P/E Ratio
N/A
$15.79
Revenue Growth
N/A
8.88
52 Week Low
$1.26
$0.72
52 Week High
$3.62
$5.78

Technical Indicators

Market Signals
Indicator
GAU
IRWD
Relative Strength Index (RSI) 45.86 42.09
Support Level $1.71 $3.08
Resistance Level $2.75 $3.95
Average True Range (ATR) 0.08 0.19
MACD 0.02 -0.07
Stochastic Oscillator 54.55 3.06

Price Performance

Historical Comparison
GAU
IRWD

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: